Product Description
Propylthiouracil is an antithyroid medicine. It works by making it harder for the body to use iodine to make thyroid hormone. It does not block the effects of thyroid hormone that was made by the body before its use was begun. This medicine is available only with your doctor's prescription. (Sourced from: https://www.mayoclinic.org/drugs-supplements/propylthiouracil-oral-route/description/drg-20072978)
Mechanisms of Action: Thyroid Hormone Synthesis Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Croatia | Cyprus | Czech | Egypt | France | Germany | Greece | Hong Kong | Hungary | India | Indonesia | Ireland | Israel | Korea | Luxembourg | Malaysia | Malta | Netherlands | New Zealand | Pakistan | Philippines | Poland | Portugal | Russia | Serbia | Singapore | Slovakia | Slovenia | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Maastricht University
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Germany
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Brain Damage, Chronic|Brain Death|Hypertension, Pulmonary|Hyperthyroidism|Intracranial Hypertension|Ischemic Stroke|Neuromyelitis Optica
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| REPO-STROKE1 | P1 |
Completed |
Neuromyelitis Optica|Brain Damage, Chronic|Brain Death|Hyperthyroidism|Ischemic Stroke|Hypertension, Pulmonary|Intracranial Hypertension |
2022-02-28 |